Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 336 of 5804
-
Experimental CAR-T therapy targets tough blood cancers in early trial
Disease control Not yet recruitingThis study is an open-label, single-arm, dose-escalation and expansion, prospective clinical trial. It enrolls patients with relapsed/refractory plasma cell disorders, administers GPRC5D CAR-T cell therapy, follows up to observe adverse reactions after medication, collects releva…
Phase: EARLY_PHASE1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New Weight-Loss drug retatrutide shows promise in phase 3 trial
Disease control OngoingThe purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
One-and-Done: new MRI-Guided radiation could transform liver cancer treatment
Disease control Recruiting nowSingle arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for Treatment-Resistant schizophrenia? phase 3 trial launches
Symptom relief Recruiting nowThis is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophre…
Phase: PHASE3 • Sponsor: Newron Pharmaceuticals SPA • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New hope for advanced bladder cancer: maintenance therapy after combo treatment
Disease control Recruiting nowThis is a single-arm, open-label, non-randomized Phase II trial evaluating the efficacy of induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 18 weeks (6 cycles), followed by maintenance pembrolizumab in treatment-naïve patients with metastatic urothelial c…
Phase: PHASE2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New cocktail of drugs takes on advanced lung cancer
Disease control Recruiting nowThis is a multicenter, open-label Phase II clinical study, with the main objective being to evaluate the investigator-assessed objective response rate of JS212 in combination therapy for advanced lung cancer. The aim is to explore the safety, tolerability, and preliminary efficac…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New asthma drug aims to cut severe attacks in half
Disease control Recruiting nowThis study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, includi…
Phase: PHASE3 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control OngoingToripalimab and bevacizumab (T-B) was approve for unresectable hepatocellular carcinoma (uHCC). Transartial therapies, including transarterial chemoembolization (TACE), hepatic artery infusion chemotherapy (HAIC), and TACE-HAIC are commonly used for uHCC. Increasing evidence show…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Weight loss shot moves to monthly dosing in new trial
Disease control Recruiting nowThis is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on b…
Phase: PHASE3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for liver transplant patients with recurrent cancer: immunotherapy combo under study
Disease control Recruiting nowThe prognosis of liver transplanted (LT) patients with recurrence of hepatocellular carcinoma (HCC), especially those with progression after locoregional treatment or advanced HCC, remains poor. Current treatment modalities involve tyrosine kinase inhibitors (TKIs) characterized …
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for hard-to-treat myeloma: experimental combo targets relapsed patients
Disease control Recruiting nowThe purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The…
Phase: PHASE2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill could help kids with rare hormone disorder cut back on steroids
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).
Phase: PHASE2, PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New program aims to save mothers with sickle cell disease in ghana
Disease control Recruiting nowThe goal of this observational study is to determine the feasibility and effectiveness of initiating a multidisciplinary sickle cell disease (SCD) obstetrics program for women with SCD in a non-academic hospital. The main question it aims to answer is: In a before-and-after stud…
Phase: NA • Sponsor: University of Ghana Medical School • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New pill combo aims to outperform current standard in CLL
Disease control Recruiting nowThe purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Gene therapy aims to restore sight in rare inherited blindness
Disease control Recruiting nowThe goal of this Clinical trial is to assess the safety and efficacy of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy (LHON)
Phase: PHASE2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New triple therapy targets hard-to-treat liver metastases in colorectal cancer
Disease control Not yet recruitingThis study is designed to evaluate the safety, tolerability, and efficacy of Epalolitovoreli Monoclonal Antibody (QL1706) combined with Fruquintinib and Short-Course Radiotherapy (SCRT), compared with standard third-line therapy, in the treatment of patients with unresectable liv…
Phase: PHASE2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug inavolisib tested for Tough-to-Treat breast cancer
Disease control Recruiting nowThe main purpose of this study is to evaluate the effectiveness of inavolisib based regimen in participants with endocrine-resistant, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-mutated, hormone receptor-positive (HR+), human epidermal gro…
Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo therapy targets childhood sarcomas that returned
Disease control Recruiting nowRAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy. Primary objective: \- To evaluate the safety of B7-H3-CAR T cell therapy after priming with hypofractionated radiation ther…
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo aims to keep early breast cancer from returning
Disease control Recruiting nowThis study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2- early breast cancer. The study planned to include 200…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for bile duct cancer: triple therapy tested in major trial
Disease control Recruiting nowThis study is a randomized, open-label, multicenter phase III clinical trial, aiming to evaluate the efficacy and safety of SHR-8068 combined with adbelimab and platinum-based chemotherapy in contrast to varicumab combined with platinum-based chemotherapy in the first-line treatm…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC